MedTrace Logo

Irinotecan (Camptosar) in Patients With Advanced Sarcomas

NCT00509860 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2013-01-03

No results posted yet for this study

Summary

Primary Objectives:

1. To determine the efficacy of the topoisomerase I (topo I) inhibitor irinotecan, delivered via a low-dose protracted schedule to patients with advanced sarcoma.
2. To determine the toxicity profile of irinotecan, using a protracted schedule, in this pretreated patient population.

Conditions

  • Sarcoma

Interventions

DRUG

Irinotecan

16 mg/m2 by vein Daily Over 1 Hour x 5 Days

Sponsors & Collaborators

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Robert S. Benjamin, MD · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-03-31
Primary Completion
2007-08-31
Completion
2012-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00509860 on ClinicalTrials.gov